|
|
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as multivitamins, blood circulation remedies, blood cancer treatments and breast cancer treatments. The Chemical Pharmaceutical segment is involved in the manufacturing and sale of therapeutic drugs for liver disease under the name of Godex, as well as the treatment of autoimmune diseases under the name of Remsima. The Other segment manufactures and sells other generic drugs. The Company distributes its products within the domestic market and to overseas markets.
Number of employees : 2 207 people.
|
|
|
| 2020 | 2021 | Delta | | Biopharmaceutical | 1 689 910.00 | 91.4% | 1 615 840.00 | 84.5% | -4.38% |
| Chemical Drugs | 242 337.00 | 13.1% | 556 711.00 | 29.1% | +129.73% |
| Others | 2 627.68 | 0.1% | 3 054.44 | 0.2% | +16.24% |
| KRW in Million |
|
|
|
| 2021 | | South Korea | 1 779 870.00 | 93.1% |
| United States | 84 608.90 | 4.4% |
| Asia | 47 119.20 | 2.5% |
| KRW in Million |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
140,791,866 |
105,582,551 |
75.0% |
2,512,503 |
1.8% |
75.0% |
|
|
|
| Name | Equities | % | | Jung-Jin Seo | 31,199,933 |
22.2% | | National Pension Service of Korea | 8,813,767 |
6.26% | | Temasek Holdings Pte Ltd. (Investment Management) | 6,931,650 |
4.92% | | The Vanguard Group, Inc. | 2,740,669 |
1.95% | | Celltrion, Inc. | 2,505,883 |
1.78% | | BlackRock Fund Advisors | 2,194,152 |
1.56% | | Norges Bank Investment Management | 1,199,318 |
0.85% | | Samsung Asset Management Co., Ltd. | 885,567 |
0.63% | | BlackRock Advisors (UK) Ltd. | 748,517 |
0.53% | | Celltrion Inc. Employee Stock Ownership ASSN. | 565,787 |
0.40% |
|
|
|
| Name | Equities | % | Valuation |
| CELLTRION PHARM, INC. (A068760) |
20,678,107 |
54.9% |
1,348,191,485 USD |
| CELLTRION, INC. (A068270) |
2,505,883 |
1.78% |
366,498,169 USD |
| BIOTOXTECH CO., LTD. (A086040) |
1,631,134 |
11.1% |
10,270,713 USD |
|
| Company contact information |
|
Celltrion, Inc. 23 Academy-ro Yeonsu-gu Inchon, Incheon 22014 Phone : +82.32.850.5000 Fax : +82.32.850.5040 Web : http://www.celltrion.com |
|
|
Sector Other Biotechnology & Medical Research
| | 1st jan. | Capi. (M$) |
 | CELLTRION, INC. | 6.57% | 21 868 |
| | | |
 | MODERNA, INC. | -30.40% | 69 156 |
| IQVIA HOLDINGS INC. | -12.01% | 46 302 |
 | LONZA GROUP AG | -25.21% | 44 721 |
| SEAGEN INC. | 9.01% | 31 083 |
| ALNYLAM PHARMACEUTICALS, INC. | 36.22% | 27 727 |
| ICON PUBLIC LIMITED COMPANY | -20.08% | 20 178 |
| BIO-TECHNE CORPORATION | -26.92% | 14 833 |
 | HANGZHOU TIGERMED CONSULTING CO., LTD. | -19.98% | 12 619 |
| PHARMARON BEIJING CO., LTD. | -20.24% | 12 519 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | -38.45% | 11 795 |
| QIAGEN N.V. | -10.65% | 11 307 |
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | 7.39% | 10 581 |
| UNITED THERAPEUTICS CORPORATION | 1.06% | 9 939 |
 | GENSCRIPT BIOTECH CORPORATION | -19.13% | 7 525 |
| SYNEOS HEALTH, INC. | -31.84% | 7 185 |
| IONIS PHARMACEUTICALS, INC. | 44.92% | 6 304 |
| CRISPR THERAPEUTICS AG | 5.75% | 6 252 |
| GINKGO BIOWORKS HOLDINGS, INC. | -58.00% | 6 220 |
| JOINN LABORATORIES(CHINA)CO.,LTD. | -0.91% | 5 799 |
| MEDPACE HOLDINGS, INC. | -16.15% | 5 657 |
Connections : Celltrion, Inc. |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
